Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and
 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
Inclusion Criteria:

 -  Asthma for at least 6 months, using inhaled corticosteroid for at least one month,
 foreced breath test less than below the normal value of the general population, -show
 an immediate improvement in breathing when given albuterol

 Exclusion Criteria:

 -  patients who have smoked in the past 6 months or are currently smoking, including
 those who smoked more than a pack of cigarettes a day for at least 10 years, -patients
 who have a history of life-threatening asthma, -patients who have had an astham
 attack, in the last 6 weeks, requiring use of systemic steroids, hospitalization, or
 ER visit, -patients who have had a respiratory tract infection or worsening asthma
 between screening or run-in periods, patients requring use of other asthma-related
 drugs during the trial, other protocol-defined inclusion/exclusion may apply